{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}],"title":"Carfilzomib Recommended Dose"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Pegylated liposomal doxorubicin recommended dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"* MTD is the maximum tolerated dose level tested unless dose limiting toxicity (DLT) are observed during Cycle 1. If DLT is observed, MTD will be the next lower dose level.\n* Please note that the maximum tolerated dose of carfilzomib and pegylated liposomal doxorubicin was not reached. The data below is the recommended dosage for further studies.","groups":[{"description":"Dose Level 0: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (27 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 1: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (36 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 2: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (45 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.\n\nDose Level 3: Carfilzomib IV (20 mg/m\\^2) D1\\&D2 of C1 and carfilzomib IV (56 mg/m\\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m\\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m\\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\\^2)D8 C1-6.","id":"OG000","title":"Phase I - Part 1"},{"description":"Cohort 0: Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG001","title":"Phase I - Part 2"},{"description":"Carfilzomib IV (56 mg/\\^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m\\^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m\\^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.","id":"OG002","title":"Phase 2"}],"paramType":"NUMBER","populationDescription":"Participants enrolled in the Phase I - Part 1 portion of this study were the only evaluable participants for this outcome measure.","reportingStatus":"POSTED","timeFrame":"28 days (completion of first cycle of all Phase I - Part 1 patients)","title":"Maximum Tolerated Dose (MTD) of Carfilzomib and Pegylated Liposomal Doxorubicin (Phase I - Part 1).","type":"PRIMARY","unitOfMeasure":"mg/m^2"}